Online inquiry

IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10048MR)

This product GTTS-WQ10048MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FN1 gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10048MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8144MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ8874MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ14627MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ4631MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ1437MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ867MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ1194MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ15787MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW